UK markets open in 4 hours 15 minutes
  • NIKKEI 225

    28,980.24
    -242.53 (-0.83%)
     
  • HANG SENG

    19,778.25
    -144.20 (-0.72%)
     
  • CRUDE OIL

    87.96
    -0.15 (-0.17%)
     
  • GOLD FUTURES

    1,778.90
    +2.20 (+0.12%)
     
  • DOW

    33,980.32
    -171.69 (-0.50%)
     
  • BTC-GBP

    19,464.40
    -567.61 (-2.83%)
     
  • CMC Crypto 200

    557.55
    -15.27 (-2.67%)
     
  • ^IXIC

    12,938.12
    -164.43 (-1.25%)
     
  • ^FTAS

    4,146.49
    -19.89 (-0.48%)
     

PCI Biotech to present at ABGSC Nordic Rare Disease Seminar

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Oslo (Norway), 29 November 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that it will present at the Nordic Rare Disease Seminar, a Stockholm based online event hosted by ABG Sundal Collier.

Today at 11:45 (CET), Dr. Per Walday, CEO, will give an online presentation focusing on the pivotal RELEASE trial with registration intent for the rare disease bile duct cancer, an orphan disease with a high unmet medical need. The presentation will be made available on PCI Biotech’s website, www.pcibiotech.com under Investors/Reports and presentations/Other presentations.

Contact information:
Per Walday, CEO
pw@pcibiotech.no
Mobile: +47 917 93 429

About PCI Biotech
PCI Biotech is a biopharmaceutical late-stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaChem (enhancement of chemotherapeutics for localised treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company’s lead programme fimaChem consists of a pivotal study in bile duct cancer, an orphan indication with a high unmet need and without approved products. fimaVacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies. fimaNAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting